Literature DB >> 1794921

Elevated serum liver enzymes in obesity: a dilemma during clinical trials.

A Golik1, A Rubio, M Weintraub, L Byrne.   

Abstract

We found that 17 out of 60 (28.3 percent) obese, otherwise healthy volunteers had elevated serum alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT) or alkaline phosphatase (AP) at least once in the course of a 12 week clinical trial. ALAT was the most commonly elevated serum aminotransferase occurring in 16 out of the 17 participants. Its range of elevation, as a percentage of the upper limit of normal (ULN) at screening was 102-164 percent (mean +/- s.d.; 127 percent +/- 18.4). Three participants had slight elevations of AP (112 percent, 113 percent, 119 percent of ULN). One participant had a minor elevation of ASAT (107 percent of ULN at screening). Of the 17 participants with elevated aminotransferases and AP, six were randomized to placebo, seven were treated with the low dose and four with the high dose of the new medication. Study participants having elevated enzymes had higher ideal body weight (IBW) than the group with normal values at screening (162 +/- 10 percent IBW, 152 +/- 11 percent IBW respectively), and at week 8 (152 +/- 3 percent IBW, 146 +/- 2 percent respectively) (P less than 0.05). The corresponding body mass index (BMI) values are 36.8 +/- 2.8 for the participants with elevated liver enzymes vs 34.2 +/- 2.6 (P less than 0.001) for the participants with normal values at screening and 34.9 +/- 3.1 and 32.8 +/- 2.8 (P = 0.02) respectively at week 8. Males (46 percent) were more likely than females (21 percent) to have elevated aminotransferases. We found no evidence for hepatic disease during the study period. Slightly elevated and fluctuating serum aminotransferases and alkaline phosphatase concentrations are a more frequent finding in healthy obese populations than previously established. In studies of anti-obesity agents investigators should broaden the entry criteria since elevated aminotransferase levels rarely interfere with the safe conduct of clinical trials in obesity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1794921

Source DB:  PubMed          Journal:  Int J Obes


  8 in total

1.  Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline.

Authors:  Zhaohui Cai; Anastasia M Christianson; Lars Ståhle; Marianne Keisu
Journal:  Eur J Clin Pharmacol       Date:  2009-06-25       Impact factor: 2.953

2.  Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population.

Authors:  A Franzese; P Vajro; A Argenziano; A Puzziello; M P Iannucci; M C Saviano; F Brunetti; A Rubino
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

Review 3.  Alkaline phosphatase: a potential biomarker for stroke and implications for treatment.

Authors:  Allison L Brichacek; Candice M Brown
Journal:  Metab Brain Dis       Date:  2018-10-04       Impact factor: 3.584

4.  PNPLA3 I148M polymorphism is associated with elevated alanine transaminase levels in Mexican Indigenous and Mestizo populations.

Authors:  Elena Larrieta-Carrasco; Victor Acuña-Alonzo; Rafael Velázquez-Cruz; Rodrigo Barquera-Lozano; Paola León-Mimila; Hugo Villamil-Ramírez; Marta Menjivar; Sandra Romero-Hidalgo; Nahúm Méndez-Sánchez; Vanessa Cárdenas; Manuel Bañuelos-Moreno; Yvonne N Flores; Manuel Quiterio; Jorge Salmerón; Fausto Sánchez-Muñoz; Teresa Villarreal-Molina; Carlos A Aguilar-Salinas; Samuel Canizales-Quinteros
Journal:  Mol Biol Rep       Date:  2014-04-02       Impact factor: 2.316

5.  The effects of cystatin C and alkaline phosphatase changes on cognitive function 12-months after bariatric surgery.

Authors:  Michael L Alosco; Mary Beth Spitznagel; Gladys Strain; Michael Devlin; Ronald Cohen; Ross D Crosby; James E Mitchell; John Gunstad
Journal:  J Neurol Sci       Date:  2014-07-22       Impact factor: 3.181

6.  Obesity is mediated by differential aryl hydrocarbon receptor signaling in mice fed a Western diet.

Authors:  Joanna S Kerley-Hamilton; Heidi W Trask; Christian J A Ridley; Eric Dufour; Carol S Ringelberg; Nilufer Nurinova; Diandra Wong; Karen L Moodie; Samantha L Shipman; Jason H Moore; Murray Korc; Nicholas W Shworak; Craig R Tomlinson
Journal:  Environ Health Perspect       Date:  2012-05-18       Impact factor: 9.031

7.  Relationship Between Obesity and Liver Enzymes Levels in Turner's Syndrome.

Authors:  Farzaneh Rohani; Fatemeh Golgiri; Mohammad Reza Alaei; Mojgan Karimi; Parham Nikraftar; Ramin Bozorgmehr
Journal:  Gastroenterology Res       Date:  2017-02-21

8.  Discovery and Validation of a Novel Neutrophil Activation Marker Associated with Obesity.

Authors:  Yue Pan; Jeong-Hyeon Choi; Huidong Shi; Liwen Zhang; Shaoyong Su; Xiaoling Wang
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.